Meta-analysis for Clinical Efficacy of Ivabradine Treating the Patients With Chronic Heart Failure / 中国循环杂志
Chinese Circulation Journal
;
(12): 960-964, 2017.
Artigo
em Chinês
| WPRIM
| ID: wpr-657567
ABSTRACT
Objective:
To systemically evaluate clinical efficacy of ivabradine (IVA) treating the patients with chronic heart failure (CHF).Methods:
We searched PubMed, Conchrane Library, EMbase, CBM, CNKI and Wanfang database to enroll the random control trials of IVA treating CHF up to 2016-10. Meta-analysis was performed by RevMan 5.2 software.Results:
A total of 12 English literature were finally enrolled which including 2 groups IVA group, n=807 and Control group, n=800. Meta-analysis showed that compared with Control group, IVA group had increased LVEF (MD=2.68, 95%CI 1.85-3.50, P<0.00001), decreased left ventricular end-diastolic volume (MD=-5.78, 95% CI -9.79 to -1.76, P=0.005), decreased left ventricular end-systolic volume (MD=-8.91, 95% CI -11.23 to -6.59, P<0.00001) and reduced N-terminal pro-brain natriuretic peptide (MD=-109.22, 95% CI -126.42 to -92.01, P<0.00001); while systolic blood pressure (MD=6.02, 95%CI -0.80 to 12.84, P=0.08) and diastolic blood pressure (MD=3.6495% CI -0.48 to 7.77, P=0.08) were similar between 2 groups.Conclusion:
IVA improved ventricular remodeling in CHF patients and had no obvious effect on blood pressure. The long-term effect and safety of IVA should be further confirmed by high quality random control trial and the result from evidence-based medicine.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Tipo de estudo:
Revisões Sistemáticas Avaliadas
Idioma:
Chinês
Revista:
Chinese Circulation Journal
Ano de publicação:
2017
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS